Question-and-Answer Session
[Operator Instructions]. Today's first question comes from Sean Levin. Sir, your line is open.
Sean Levin - Lazard Capital
Thank you. Congratulations on another strong quarter.
Benjamin Gong - Vice President of Finance
Thanks Sean.
Sean Levin - Lazard Capital
Sure. My first question has to do with hysterectomy. We have done a lot of survey work here, and it seems that the simple procedures, as you said, seem to picking up quite a bit of steam here. In the past, you have mainly talked about looking malignant or complex procedures. We are wondering if you could you could give a little bit more detail on what you are seeing on the benign or simple arena.
Lonnie M. Smith - Chairman and Chief Executive Officer
I think I would even make a different distinction. I don't think benign by definition means simple. There are complex benign and we are seeing a lot of traction within both complex benign and I think by definition all malignant which is also complex. That remains our initial target. There is no question about it. We have the highest value to add within those complex surgeries.
We have, however, seen centers that flipped the majority and in some cases all of their hysterectomies to da Vinci. But in terms of where we are targeting, where we believe the highest value is, it really boils down to our patient value equation and that really is in the complex hysterectomy, which by our definition, is probably over around the 0.24 million of procedures U.S.
Sean Levin - Lazard Capital
Okay. And then just one other question on the Power Medical deal that you announced during the quarter. Could you give us some timeline on products on this and what procedures might benefit?
Lonnie M. Smith - Chairman and Chief Executive Officer
I'll take the second part and then I'll turn the first part over to Gary Guthart. The second part in terms of the procedures that might benefit from it. If look at the tools that are used throughout surgery as surgical stapling is found in many surgical specialties and you will find general surgery, thoracic surgery, GYN, GYN/oncology, urology and so and so forth.
So many of those procedures in many of those specialties have da Vinci within them. However it is just not a perfect choreography between the stapling application and the general dissection and reconstruction and visualization. So the answer is, we think it will potentially have a place in multiple specialties. Colorectal is an area where there is a lot of stapling, lung resections, a lot of stapling. And we will see ultimately when you get it. But there are plenty of targets we believe. Now as far as the actual development I'll let Gary comment on that.
- To read the full transcript on Seeking Alpha, click here »
